Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Salicylamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.58 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 5/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylamide SCHEMBL4949313 | 1.00 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL27956358 | 1.00 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL27497234 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL29384763 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL21646 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL7198790 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL473700 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL11412975 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL18729462 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL11599751 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| EP-3921329-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2021-12-15 | — | — | EP | disclosed |
| US-20210205406-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-07-08 | — | — | US | disclosed |
| CN-112930198-A | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2021-06-08 | — | — | CN | disclosed |
| CN-107970209-B | Improved parenteral formulations of lipophilic pharmaceutical agents and methods of making and using the same | 普拉福姆五金器具第二有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020161602-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2020-08-13 | — | — | WO | disclosed |
| EP-3628047-A1 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-01 | — | — | EP | disclosed |
| CN-106459024-B | Cyclopropyl amine compounds and application thereof | 武田药品工业株式会社 | 2019-11-05 | — | — | CN | disclosed |
| CN-109867660-A | Tetrahydroisoquinoline amide compound and its medicinal usage containing quaternary ammonium ion | 四川科伦博泰生物医药股份有限公司 | 2019-06-11 | — | — | CN | disclosed |
| WO-2008054726-A2 | TARGETING NBS1-ATM INTERACTION TO SENSITIZE CANCER CELLS TO RADIOTHERAPY AND CHEMOTHERAPY | SOUTHERN RESEARCH INSTITUTE (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007090194-A2 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007076501-A2 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-5925659-A | SUBSTITUTED 4-HYDROXAMIDO-2-PHENYL-OXAZOLINES FOR TREATMENT OF GRAMNEGATIVE BACTERIAL INFECTIONS | MERCK & CO., INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0382157-A1 | Microbiological chiral reduction of carbonyl groups and novel microorganism | SCHERING CORPORATION (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4948732-A | CONTACTING WITH ASPERGILLUS NIVEUS IN CULTURE MEDIUM | SCHERING CORPORATION (US) | 1990-08-14 | — | — | US | disclosed |
| US-4879233-A | DILEVALOL | SCHERING CORPORATION (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0312283-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restrictions in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | disclosed |
| EP-0009702-A1 | A phenylalkylaminoethylsalicylamide, its preparation and pharmaceutical compositions containing it | SCHERING CORPORATION (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CA2 2499/4885GAA 2064/4885KDM4E 1474/4885 |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | CA2 4477/4885GAA 1916/4885KDM4E 2713/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CA2 2499/4885GAA 2064/4885KDM4E 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.